Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study

Matteo Santoni, Francesco Massari, Hideki Takeshita, José Carlos Tapia, Michele Dionese, Renate Pichler, Mimma Rizzo, Elaine T. Lam, Enrique Grande, ROBERT COLEMAN KEMP, Javier Molina‐Cerrillo, Fabio Calabrò, Deniz Tural, Zsófia Kürönya, Jakub Kucharz, Ondřej Fiala, Emmanuel Seront, Ray Manneh Kopp, Halima Abahssain, Jindřich Kopecký, Angelo Martignetti, Ravindran Kanesvaran, Roubini Zakopoulou, Jawaher Ansari, Johannes Landmesser, Veronica Mollica, Camillo Porta, Joaquim Bellmunt, Samer Salah, Daniele Santini